MRRBIZ includes new market research report "China Blood Product Industry Report, 2014-2017" to its large collection of research report.
Albany, NY -- (SBWIRE) -- 07/14/2014 -- Plasma resource reserves and control are crucial to the development of blood products industry. Although the closure of 16 plasma collection stations in Guizhou in 2011 didn’t cause major disruption to domestic blood products market, the total plasma volume in China blood products industry reduced by 2.8% year on year and total lot release volume declined by 7% from a year earlier in 2013, due to stock consumption, insufficient utilization of new plasma stations and production break of some companies (e.g. Guizhou Taibang Biological Products Co., Ltd and Guangdong Wellen Biological Pharmaceutical Co., Ltd. on account of upgrading and reconstruction, Shanghai RAAS Blood Products Co., Ltd. affected by floods).
Browse Full Report with Toc:
However, some niche varieties of blood products, such as scarce human coagulation factor VIII, maintained higher growth in lot release volume. In 2013, the human coagulation factor VIII produced by Shandong Taibang and CNBG Shanghai Institute of Biological Products were approved for release and came into the market, making the lot release volume of the product during the same period amount to 526,000 bottles, soaring by 44.5% on year-on-year basis.
Because of robust demand from China blood products market, the total lot release volume of imported human albumin reached 14.39 million bottles (about 10g/bottle) in 2013, a year-on-year increase of 24.1%, accounting for 53.4% (45.3% in 2012) of the total lot release volume of human albumin during the same period. Assuming absolute superiority, Behring, Baxter, Grifols and Octapharma still held the ground as the top four exporters of human albumin to China.
For Download Full Report with Toc: http://www.marketresearchreports.biz/sample/sample/211596
Despite a slight year-on-year decline in output and sales volume, major Chinese blood products companies, by and large, maintained steady revenue growth in 2013, thanks to rising prices of blood products (the highest retail prices of fibrinogen and blood coagulation factor VIII rose over 50% year on year). China Biologic Products, Hualan Bio, Tiantan Biological Products, Shanghai RAAS and Yuanda Shuyang Pharmaceutical, which hold combined 60% of the total plasma volume, generated total revenue of about RMB4.2 billion in 2013, up 13.5% year on year. Among them, Shanghai RAAS, due to production halt caused by flood, earned only RMB496 million, down 25.1% year on year.
Inquiry Before Buying Rpeort: http://www.marketresearchreports.biz/analysis/211596
MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries. Kindly visit: http://www.marketresearchreports.biz/.